Detecting Volemic, Cardiac, and Autonomic Responses From Hypervolemia to Normovolemia via Non-Invasive ClearSight Hemodynamic Monitoring During Hemodialysis: An Observational Investigation

Chih-Jun Lai1-2†, Chung-Chih Shih3†, Hsing-Hao Huang2, Ming-Hung Chien4, Ming-Shiou Wu4 and Ya-Jung Cheng3*

1Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan, 2Department of Anesthesiology, National Taiwan University Hospital, Taipei, Taiwan, 3Department of Anesthesiology, National Taiwan University Cancer Center, Taipei, Taiwan, 4Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Background: Unstable hemodynamics are not uncommon during hemodialysis (HD), which involves a rapid volume depletion, taking the patient from hypervolemia toward euvoemla. Since uremic patients commonly have cardiovascular comorbidities, hemodynamic changes during HD may reflect interactions among the volemic, cardiac, and autonomic responses to gradual volume depletion during ultrafiltration. Accurate identification of inappropriate responses helps with precisely managing intradialytic hypotension. Recently, the non-invasive ClearSight was reported to be able to detect causes of intraoperative hypotension. In this prospective observational study, we aimed to determine whether ClearSight could be used to detect patterns in stroke volemic, cardiac, and vasoreactive responses during HD.

Methods: ClearSight was used to monitor chronic stable patients receiving maintenance HD. Data of mean arterial blood pressure (MAP), heart rate (HR), stroke volume index (SVI), cardiac index (CI), and calculated systemic vascular resistance index (SVRI) were obtained and analyzed to examine patterns in volemic, cardiac, and vasoreactive changes from T0 (before HD) until T8 in 30-min intervals (total 4 h).

Results: A total of 56 patients with a mean age of 60.5 years were recruited, of which 40 of them were men. The average ultrafiltration volume at T8 was 2.1 ± 0.8 L. The changes in MAP and HR from T0 to T8 were non-significant. SVI at T7 was significantly lower than that at T1, T2, and T3. CI at T4 to T8 was significantly lower than at T0. SVRI was significantly higher at T3 to T8 than at T0. Pearson’s correlation coefficients between SVI and CI and between SVRI and MAP were positive at all time points. The correlation coefficients between SVRI and SVI and between CI and SVRI were significant and negative for all time points.
INTRODUCTION

The goal of hemodialysis (HD) is to restore the intracellular and extracellular fluid environment through diffusion and ultrafiltration (Himmelfarb and Ikizler, 2010). Theoretically, HD is aimed at programmed volume removal, to take the patient from a hypervolemic state to either a euvolemic or a slightly hypovolemic state with well-maintained circulation. Although fluid removal (ultrafiltration) is believed to be the most important aspect of the process, hemodynamic management is also challenging in the event of unpredictable cardiac and vascular responses to fluid removal because of the high prevalence of cardiovascular disease in uremic patients undergoing HD (Cozzolino et al., 2018). Precise management of intradialytic hypotension is difficult without accurate identification of the cause via simultaneous monitoring of the volemic, cardiac, and vasoreactive responses to the gradual volume depletion during HD. Hypotension due to delayed vasoreactive responses to volume depletion can be managed by reducing the ultrafiltration rate, maintaining observation, and administrating vasoconstrictors. Hypotension due to decreased CI can be managed by stopping further volume depletion or administering inotropic to maintain adequate systemic circulation.

For patients receiving HD, it is preferable to use a non-invasive, well-tolerated, and continuous monitoring system to detect hemodynamic changes along with HD. In addition, the system should be able to demonstrate the trends with gradual volume depletion from hypervolemia, normovolemia, or even hypovolemic state. It may help on adjusting the goal and speed of ultrafiltration because different cardiac effects from chronic fluid overload was also reported in patients receiving HD (Antlanger et al., 2013). Most previous monitoring systems, such as stroke volume variation (SVV) (Yoshihara et al., 2017), Doppler echocardiography (Nitta et al., 1989), and photoplethysmography (PPG) signals (Sandberg et al., 2014), focused on volemic changes. However, there are many other associated risk factors for hypotension that are not investigated, such as shifts in extracellular volume, altered vasoregulation (Reilly, 2014), inappropriate reduction of the sympathetic tone, and an increase in venous capacity (Daugirdas, 2001). The low total peripheral resistance index (TPRI) and cardiac power index (CPI) have recently been reported to be associated with the highest 1-year mortality rates in patients receiving HD (Doenyas-Barak et al., 2019). Therefore, monitoring the autonomic and cardiac responses that accompany volemic changes is crucial for ensuring a well-maintained circulation, especially for high-risk patients. At present, since intradialytic hypotension is still considered the most important complication during HD (Radziszewski and Sulowicz, 2006), periodic blood pressure (BP) measurement with non-invasive blood pressure (NIBP) and heart rate (HR) monitoring remains the routine monitoring procedure during HD, although a continuous, non-invasive monitoring system has been reported to be preferable for each episode of HD for high-risk patients (Leypoldt and Lindsay, 1999). Few monitoring systems are able to determine volemic, cardiac, and vasoregulatory responses to HD simultaneously. Since parametric feedback is helpful for differentiating the volemic, cardiac, and vasoregulatory responses to HD, as well as for the optimal management of hemodynamic instability, a well-tolerated, non-invasive monitoring system that monitors multiple parameters is indicated.

ClearSight (Edwards Lifesciences, Irvine, CA, United States) is a validated non-invasive continuous BP monitoring system (Kim et al., 2019; Lee et al., 2020). It has been reported to reduce intraoperative hypotension (Maheshwari et al., 2018) by facilitating well-informed decisions about volume administration and the adjustment of the vascular tone in moderate-to-high-risk surgery (Martina et al., 2012). In addition to continuously monitoring BP, ClearSight provides continuous measurements of the stroke volume index (SVI) and cardiac index (CI) as well as the calculated systemic vascular resistance index (SVRI) over time. In this observational study, we used both ClearSight and conventional NIBP monitor. We aimed to test whether the parameters SVI, CI, and calculated SVRI could reveal the trends in volemic, cardiac, and vasoconstrictive responses to gradual volume depletion during HD, which involves the unique situation of progressing from hypervolemia to normovolemia.

METHODS

We enrolled chronic stable patients receiving maintenance HD three times a week for at least 6 months at the outpatient HD unit of our hospital, National Taiwan University Hospital (a tertiary care center in Taipei, Taiwan), from June 2017 to November 2018. We recruited adult patients aged >20 years, who had sinus rhythm, and a stable dry weight but without evidence of fluid overload (i.e., they exhibited no clinical signs of fluid overload, such as shortness of breath). Patients were excluded if they had been admitted for thrombosis of vascular access or acute cardiovascular events (stroke, acute coronary
syndrome, arrhythmia including atrial fibrillation, or decompensating heart failure) in the previous 3 months or if they had Raynaud’s disease, peripheral arterial occlusion disease, or a local skin defect on hands or fingers. The Research Ethics Committee of our institution approved (approval number: 201702064RIPB) the study, and all participants provided written informed consent prior to participating. Our investigation is registered at http://clinicaltrials.gov with the identifier NCT03901794.

**NIBP Monitoring Application**

After arriving in the HD room, the patients lay on the bed, and the standard hemodynamic monitoring (including pulse oximetry and electrocardiography) was conducted. In addition, the ClearSight system was attached to the hand without an arteriovenous fistula. An appropriately sized finger cuff was applied to the middle phalanx of the second or third finger. Data were continuously collected throughout the HD session.

**High-Efficiency HD Protocol**

High-efficiency HD was performed by the same group of staff in accordance with the standard protocol at our outpatient HD unit. The dialysis was delivered using the conventional HD machines (Fresenius 4,008, Fresenius Medical Care, Bad Homburg, Germany) using Fresenius dialyzers (FX60/FX80/FX100 and Polysulfone, Fresenius Medical Care). The blood flow was set between 200 and 350 ml/min, and the dialyzate flow was set to 500 or 800 ml/min. The default dialyzate composition was bicarbonate at 32 mEq/L, potassium at 2.0 mEq/L, sodium at 136–140 mEq/L, and calcium at 2.5–3.0 mEq/L. Each dialysis session lasted 4 h. All routine laboratory data were collected monthly.

The target volume for ultrafiltration was set before the initiation of HD. Intrahemodialytic hypotension (IDH) was recorded based on automatic NIBP by HD nurses. IDH was defined as pre-HD systolic blood pressure (SBP) minus minimum intradialytic SBP ≥ 30 mmHg and minimum intradialytic SBP < 90 mmHg (Flythe et al., 2015).

**Data Collection and Analysis**

We collected the following demographic data: age, sex, weight, height, clinical records (including diabetes mellitus, hypertension, and cardiac vascular disease), and number of years on dialysis. The following consecutive data, recorded at 30-min intervals, were prospectively collected from the patients’ records by HD nurses: ultrafiltration volume, sequential NIBP data, IDH, and the subsequent management. The data (mean arterial blood pressure [MAP], HR, SVI, and CI) were collected by another observer, from the initiation of HD (T0) to its conclusion 4 h later (T8) at 30-min intervals, from the continuous-monitoring data recorded by the ClearSight system. The ClearSight acquisition system allowed the export of raw data, including SBP to a spreadsheet (Microsoft Excel, Microsoft Corporation, Redmond, WA, United States). The data for each patient used to calculate IDH were analyzed in MATLAB 2019b (MathWorks, Natick, MA, United States). We presented the mean number of episodes per patient during hemodialysis. The SVRI was calculated by the ClearSight system based on the assumption that central venous pressure (CVP) taken as 10 cmH2O.

**TABLE 1 | Patient characteristics (N = 56).**

| Variable                  | Value                        |
|---------------------------|------------------------------|
| Age (years)               | 60.5 ± 14.1                  |
| Sex (male/female; n)      | 40/16                        |
| Height (cm)               | 164.9 ± 7.4                  |
| Weight (kg)               | 66.0 ± 15.7                  |
| BMI                       | 24.09 ± 4.6                  |
| Comorbidities (n/%)       |                              |
| Diabetes mellitus         | 19 (33.9%)                   |
| Hypertension              | 30 (53.6%)                   |
| Cardiac disease           | 17 (30.4%)                   |
| Dialysis vintage (months) | 70.1 ± 55.7                  |

Data presented are mean ± SD or n (%). BMI, body mass index.

**Statistical Analyses**

Continuous data are presented as mean and standard deviation. Repeated measures analysis of variance (ANOVA) with Bonferroni post hoc tests was used to statistically analyze the differences between the nine time points (T0 to T8, from 0 to 4 h in 30 min increments) in terms of ultrafiltration volume, MAP, CI, SVRI, SVI, and HR. To assess potential relationships between these variables at each time point, we used Pearson’s correlation coefficients. p values < 0.05 were considered statistically significant. Analyses were performed using SPSS (SPSS Inc., Chicago, IL, United States).

**RESULTS**

**Patient Characteristics**

We recruited 56 patients who were receiving chronic HD, of which 40 were male. They had a mean age of 60 years. Demographic data, comorbidities, and hemodialysis vintage are summarized in Table 1.

**Changes in Ultrafiltration Volume Changes**

As shown in Figure 1A; Table 2, the ultrafiltration volume increased significantly from T0 to T8. The values for each time point were significantly different from those for all other time points (p < 0.001 for all comparisons). For example, the ultrafiltration volume value at T8 was significantly higher than that at T0. The average ultrafiltration volume at T8 was 2.1 ± 0.8 L, and the ultrafiltration rate was 8.2 ± 3.5 ml/kg/hr. The change in dry weight was −0.5 ± 0.18 kg. Hypotension was managed through close observation and reducing the ultrafiltration rate, which was sufficiently effective without medications. All patients completed their HD having achieved their preset goals.

**Changes in MAP Detected by ClearSight**

The MAP at T1 to T8 did not differ significantly from MAP before hemodialysis (T0) (Table 2; Figure 1B). The mean number of IDH episodes per patient was 16.74.

**Changes in SVI Detected by ClearSight**

The SVI values differed significantly among the time points (Table 2; Figure 1C). The post hoc comparisons between the values at every time point are presented in Table 3. The values at
T7 were significantly lower than those at T1, T2, and T3, and the differences were -4.15 ± 1.10 ml/m² ($p = 0.018$), -3.75 ± 1.09 ml/m² ($p = 0.045$), and -2.96 ± 0.85 ml/m² ($p = 0.041$), respectively.

**Changes in HR Detected by ClearSight**
The HR at T1 to T8 did not differ significantly from T0 (Table 2; Figure 1D).

**Changes in CI Detected by ClearSight**
The CI values differed significantly among the time points (Table 2; Figure 1E). The post hoc comparisons of values at every time point are shown in Table 4. The CI at T4, T5, T6, T7, and T8 was significantly lower than that at T0, and the differences were -0.39 ± 0.10 ($p = 0.01$), -0.41 ± 0.10 ($p = 0.01$), -0.38 ± 0.11 ($p = 0.044$), -0.46 ± 0.10 ($p = 0.001$), and -0.42 ± 0.12 ($p = 0.03$), respectively.

**Changes in SVRI Detected by ClearSight**
The calculated SVRI was significantly higher at T3 to T8 than that at T0 (Table 2; Figure 1F). The post hoc comparisons of the values at every time point are shown in Table 5. The differences were 378.82 ± 90.21 ($p = 0.005$), 410.46 ± 81.96 ($p < 0.001$), 408.86 ± 107.28 ($p = 0.02$), 482.96 ± 111.73 ($p = 0.003$), 532.78 ± 146.89 ($p = 0.03$), and 586.09 ± 160.60 ($p = 0.03$).

**Pearson’s Correlations Between Time Points**
The relationships between CI, SVI, SVRI, HR, MAP, and ultrafiltration volume at all time points are presented in Table 6. The range of Pearson’s correlation coefficient between CI and SVI was 0.76–0.87 among all time points (T0 to T8, $p < 0.001$ for all).
TABLE 2 | Trends in data on ultrafiltration volume and from the ClearSight monitoring system.

| Variable          | Time point | p-value     |
|-------------------|------------|-------------|
|                  | T0         | T1          | T2          | T3          | T4          | T5          | T6          | T7          |
| Ultrafiltration   | 18.91 (7.68) | 298.75 (115.50) | 572.64 (224.37) | 841.02 (33.44) | 1109.48 (439.04) | 1377.27 (547.66) | 1639.55 (654.95) | 1887.16 (752.15) |
| MAP (mmHg)        | 83.34 (17.38) | 94.73 (17.38) | 96.23 (10.01) | 94.98 (11.65) | 93.67 (11.70) | 92.03 (11.70) | 94.12 (11.70) | 92.07 (11.70) |
| SVI (ml/m²)       | 43.56 (12.41) | 43.33 (10.01) | 42.93 (11.98) | 42.14 (11.65) | 40.68 (11.70) | 39.95 (11.70) | 40.06 (11.70) | 39.18 (11.70) |
| HR (beat/min)     | 78.34 (10.14) | 76.85 (10.23) | 74.96 (9.74) | 74.37 (10.23) | 74.26 (10.64) | 76.04 (14.71) | 76.29 (13.77) | 76.53 (15.19) |
| CI (L/min/m²)     | 3.38 (0.93) | 3.28 (0.69) | 3.17 (0.77) | 3.08 (0.79) | 2.98 (0.79) | 2.97 (0.79) | 3.00 (0.85) | 2.92 (0.81) |
| SVRI (dynes·s/cm²) | 2211.72 (814.28) | 2194.54 (885.62) | 2165.65 (1006.50) | 2000.55 (772.51) | 2632.18 (734.24) | 2635.55 (850.68) | 2704.68 (898.04) | 2704.50 (1198.67) |

Data are presented as mean (standard deviation); CI, cardiac index; HR, heart rate; MAP, mean arterial pressure; SVI, stroke volume index; SVRI, systemic vascular resistance index. T0 to T8, from before hemodialysis (T0) to 240 min later (T8).

DISCUSSION

Our results show that ClearSight is able to detect patterns in volemic, cardiac, and vasoreactive changes even in uremic patients starting from the hypervolemic state. ClearSight is a well-tolerated, non-invasive monitoring system for 4-h HD and is not affected by the patient moving their hands or eating during the HD session. We detected 16.74 episodes per patient with gradual volume depletion during HD, although our results revealed similar blood pressure throughout HD. We detected 16.74 episodes per patient of hypotension, and based on simultaneous and continuous monitoring, this was not associated with low SVI or CI. Close observation and reducing the HD rate were effective for returning BP to normal levels without medications. Based on our results, the most intradialytic hypotension was associated with delayed or inadequate vasoreactivity during each 30-min interval but not with ultrafiltration volume. Reducing the filtration rate may be effective for stabilizing BP long enough for adequate autonomic responses to be initiated. Once the BP had normalized, the filtration rate was returned to its original value, and HD was completed.

The direction of the changes in the volume status during HD reflected the patients’ progression from a hypervolemic plateau back to the normally responsive range, according to Flank–Starling law (Malbrain et al., 2015). The SVI decreased slightly but remained relatively constant from T0 to T6. Based on our results, the decreases in SVI were not correlated with ultrafiltration volume. The patterns of change in SVI, when the patient progresses from hypervolemia to euvolemia, are rarely discussed in the literature, relative to those in hypovolemia. In the hypervolemic state (T0 to T2), SVI remained relatively constant in spite of the higher rate of fluid removal with a relatively constant SVRI. The plasma refill may occur via refilling of the vascular space from the interstitial and cellular compartments or from venous blood reservoir (Greenway and Lister, 1974). The SVI would therefore be well-maintained despite the change in volume because of the increased venous capacity that exists in uremic patients before HD.

Our results revealed an inflection point at which the vasoreactive response is activated. SVRI did not increase significantly until T3, but thereafter (T3 to T8) it increased and was correlated with the ultrafiltration volume. The passive leg raising (PLR) test has been shown to effectively identify vasopressor-dependent circulatory shock (Krige et al., 2016). Another study, in which PLR was performed during the second hour of HD, found that BP increased during PLR (Erdem, 2016). Our results agree with that report; however, if PLR was performed before HD, it was impossible to identify a hypervolemic state based on it.
The SVRI acts as a sentinel for autonomic responses to volume depletion under normovolemic or hypovolemic conditions that serve to maintain adequate circulation. A consistently elevated SVRI also indicates well-compensated vasoconstriction. When the patterns of change in SVRI and CI are similar, it is possible to differentiate autonomic and cardiac responses to gradual volume depletion. Simultaneous monitoring may help to manage unstable hemodynamics because possible cardiac stunning associated with HD has been previously reported (Power et al., 2016). However, according to the same assumption about CVP that we used to calculate SVRI in this study, the slope of the change in SVRI should be much steeper in that situation than it is in the illustrated figure.

We recorded 16.74 IDH episodes per patient during HD. The changes in CI are crucial for identifying inadequate circulation and determining necessary management steps, such as initiating treatment with inotropic drugs or vasopressors. Our results showed that CI decreased significantly from T4 onward but was nevertheless well maintained until T8. The CI data obtained in this study are similar to those obtained using another non-invasive
bioreactance cardiac output monitoring system (NICOM) (Bernardo et al., 2015). Since we did not include patients with cardiac dysfunction, CI remained within the normal range throughout HD. However, the clinical importance of monitoring CI may differ between uremic patients with and without cardiovascular diseases (Fuehrlein et al., 2007). With the continuous monitoring of SVI, any further decrease in SVI or CI can be detected before severe hypotension occurs. Our results showed that the hypotension that occurred during HD was associated with temporally inappropriate vasoreactivity but not low stroke volume or CI.

The monitoring trends in SVI, HR, CI, and SVRI should be beneficial during HD for high-risk patients with limited cardiac function, possible autonomic neuropathy, unknown pre-HD volume status, comorbidity manifestations, or restricted protein or fluid intake (Chan et al., 2019). In addition to identification of hypotension, it would facilitate the identification of pre-HD hypovolemia, adjustment of filtration goals, or provision of early cardiac support, which may prevent cardiovascular problems associated with HD. However, ClearSight may be too costly for routine application during each HD session, and specific expertise is required for differential diagnosis. Based on the principles of “goal-directed dialysis care” (Chan et al., 2019), we suggest that ClearSight is used for patients with higher cardiovascular risks before their chronic stability is established.

The study has some limitations as follows: first, the effect of patients’ medication on any associated underlying disease could not be evaluated. Second, our study had a small sample size. Third, we assumed a CVP level of 10 cmH2O, which may have been a limitation in terms of obtaining a reliable continuous estimation of SVRI. Fourth, the more detailed hemodynamic changes in the parameters measured using ClearSight particularly CI and the relevant mechanisms associated with IDH should be further investigated, even though we did assess IDH in this study.

In conclusion, ClearSight is a well-tolerated practical system for simultaneous monitoring of the volume status and the autonomic response, even under gradual volume depletion from a hypervolemic status. By observing the trends in systemic vascular resistance and cardiac output in addition to blood pressure, this easy-to-use, non-invasive monitoring system may provide more information on determining pre-HD status, responses to ultrafiltration, and effective hemodynamic managements during HD.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Ethics Committee of National Taiwan University Hospital (201702064RIPB).

REFERENCES

Antlanger, M., Hecking, M., Haidinger, M., Werzowa, J., Kovarik, J. J., Paul, G., et al. (2013). Fluid Overload in Hemodialysis Patients: a Cross-Sectional Study to Determine its Association with Cardiac Biomarkers and Nutritional Status. BMC Nephrol. 14, 266. doi:10.1186/1471-2369-14-266

Bernardo, J. F., Kim, H., and Pinsky, M. R. (2015). Characterization of Cardiovascular Health for Chronic Dialysis Patients Using Continuous Non-invasive Cardio Output Monitoring. J. Clin. Nephrol. Res. 3, 1028. Available at: https://www.jscimedcentral.com/Nephrology/nephrology-3-1028.pdf

Chan, C. T., Blakestijn, P. J., Dember, I. M., Gallieni, M., Harris, D. C. H., Lok, C. E., et al. (2019). Dialysis Initiation, Modality Choice, Access, and Prescription: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 96, 37–47. doi:10.1016/j.kint.2019.01.017

Cazzolin, M., Mangano, M., Stocchi, A., Ciceri, P., Conte, F., and Galassi, A. (2018). Cardiovascular Disease in Dialysis Patients. Nephrol. Dial. Transpl. 33, iii28–iii34. doi:10.1093/ndt/gfy174

Daugirdas, J. T. (2001). Pathophysiology of Dialysis Hypotension: An Update. Am. J. Kidney Dis. 38, S11–S17. doi:10.1053/akjkd.2001.28090

Doenys-Barak, K., de Abreu, M. H. F. G., Borges, L. E., Tavares Filho, H. A., Yunlin, F., Yurong, Z., et al. (2019). Non-invasive Hemodynamic Profiling of Patients Undergoing Hemodialysis – a Multicenter Observational Cohort Study. BMC Nephrol. 20, 347. doi:10.1186/s12882-019-1542-4

Erdem, E. (2016). The Effects of Passive Leg Raising and Ultrafiltration Stopping on Blood Pressure in Hemodialysis Patients. Int. Urol. Nephrol. 48, 877–882. doi:10.1007/s11255-016-1261-8

Flythe, J. E., Xue, H., Lynch, K. E., Curhan, G. C., and Brunelli, S. M. (2015). Association of Mortality Risk with Various Definitions of Intradialytic Hypotension. JASN 26, 724–734. doi:10.1681/asn.2014020222

Fuerhrench, B., Meller, K., and Ross, E. A. (2007). Alar Photoplethysmography: a New Methodology for Monitoring Fluid Removal and Carotid Circulation during Hemodialysis. J. Clin. Monit. Comput. 21, 211–218. doi:10.1007/s10787-007-9075-y

Greenway, C. V., and Lister, G. E. (1974). Capacitance Effects and Blood Reservoir Function in the Splanchnic Vascular Bed during Non-hypotensive Haemorrhage and Blood Volume Expansion in Anaesthetized Cats. J. Physiol. 237, 279–294. doi:10.1113/jphysiol.1974.sp010482

Himmelfarb, J., and Ikizler, T. A. (2010). Hemodialysis. N. Engl. J. Med. 363, 1833–1845. doi:10.1056/NEJMr1009270

Kim, J., Chou, E. F., Le, J., Wong, S., Chu, M., and Khine, M. (2019). Soft Wearable Pressure Sensors for Beat-to-Beat Blood Pressure Monitoring. Adv. Healthc. Mater. 8, 1900109. doi:10.1002/adhm.201900109

Krige, A., Bland, M., and Fanshawe, T. (2016). Fluid Responsiveness Prediction Using Vigileo FloTrac Measured Cardiac Output Changes during Passive Leg Raise Test. J. Intensive Care 4, 63. doi:10.1186/s40566-016-0188-6

Lee, S., Chung, J., Bae, J., Cho, Y. J., Nam, K., and Jeon, Y. (2020). Continuous Non-invasive Arterial Pressure Monitoring (ClearSight System) and Ankle Blood Pressure Measurements as Alternatives to Conventional Arm Blood Pressure. Jem 9, 3615. doi:10.3390/jem9113615

AUTHOR CONTRIBUTIONS

Y.C.C designed the study. Y.C.C conducted the study. C-JL and C-CS analyzed the data. C-JL and Y.C.Y wrote the main manuscript. C-JL prepared the figures. All authors reviewed the manuscript.

FUNDING

This work was partially supported by the Yuen-Ta research foundation.

Leypoldt, J. K., and Lindsay, R. M. (1999). Hemodynamic Monitoring during Hemodialysis. Adv. Ren. Replace. Ther. 6, 233–242. doi:10.1016/s1073-4449(99)70019-1

Maheshwari, K., Khanna, S., Bajracharya, G. R., Makarova, N., Riter, Q., Raza, S., et al. (2018). A Randomized Trial of Continuous Noninvasive Blood Pressure Monitoring during Noncardiac Surgery. Anesth. Analg. 127, 424–431. doi:10.1213/ane.0000000000003482

Malbran, M. L. N. G., De Waele, J. J., and De Keulenaer, B. L. (2015). What Every ICU Clinician Needs to Know about the Cardiovascular Effects Caused by Abdominal Hypertension. Anesthesiol. Intensive Ther. 47, 388–399. doi:10.5603/AT.a.2015.0028

Martina, J. R., Westerhof, E. B., van Goudoever, J., de Beaumont, E. M. F. H., Truijen, J., Kim, Y.-S., et al. (2012). Noninvasive Continuous Arterial Blood Pressure Monitoring with Nexfin. Anesthesiology 116, 1092–1103. doi:10.1097/ALN.0b013e31824b94ed

Nitta, M., Takamoto, T., Yajima, T., Adachi, H., Tanaka, C., Chida, Y., et al. (1989). Effects of Hemodialysis on Left Ventricular Performance: a Doppler Echocardiographic Study. J. Cardiol. 19, 1117–1125.

Power, A., Charitaki, E., and Davenport, A. (2016). Changes in Vascular Tone Occur Early during Hemodialysis Treatments Independently of Volume Reduction. Artif. Organs 40, 678–683. doi:10.1111/aor.12610

Radziszewski, A., and Sulowicz, W. (2006). Pathogenesis and Treatment of Dialysis Hypotension. Kidney Int. 70, 536–539. doi:10.1016/s0075-2402(06)01712-0

Reilly, R. F. (2014). Attending Rounds: A Patient with Intradialytic Hypotension. Cijss 9, 798–803. doi:10.2215/cjn.09930913

Sandberg, F., Baulin, R., Hernando, D., Laguna, P., Martinez, J. P., Solem, K., et al. (2014). Prediction of Hypotension in Hemodialysis Patients. Physiol. Meas. 35, 1885–1898. doi:10.1088/0967-3334/35/9/1885

Yoshihara, F., Kishida, M., Ogawa, K., Nishigaki, T., Nakasaki, H., Ishizuka, A., et al. (2017). High Stroke Volume Variation Is an Independent Predictor for Decreased Blood Pressure during Hemodialysis. Ther. Apher. Dial. 21, 166–172. doi:10.1177/1744-9987.12511

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lai, Shih, Huang, Chien, Wu and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.